Bessemer Group
PHAT icon

Bessemer Group’s Phathom Pharmaceuticals PHAT Stock Holding History

Bessemer Group’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-325
Closed -$3K – 2682
2024
Q2 		$3K Buy
+325
New +$3.35K ﹤0.01% 1886
2022
Q2 		– Sell
-101
Closed -$1K – 1992
2022
Q1 		$1K Hold
101
– – ﹤0.01% 1784
2021
Q4 		$2K Hold
101
– – ﹤0.01% 1772
2021
Q3 		$3K Hold
101
– – ﹤0.01% 1579
2021
Q2 		$3K Hold
101
– – ﹤0.01% 1484
2021
Q1 		$4K Buy
+101
New +$4.23K ﹤0.01% 1417

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Bessemer Group's PHAT Position: Q3 2024 in Review

Bessemer Group sold out of Phathom Pharmaceuticals (PHAT) in Q3 2024, closing a stake of 325 shares — an estimated $3K sold.

Bessemer Group first reported a position in PHAT in Q1 2021 and held it in 6 quarters. The position peaked at $4K in Q1 2021. 133 funds tracked by Wall St. Rank hold PHAT as of Q3 2024.

  • Bessemer Group reported no remaining Phathom Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Bessemer Group sold 325 Phathom Pharmaceuticals shares in Q3 2024, an estimated $3K.
  • Bessemer Group first reported a position in Phathom Pharmaceuticals in Q1 2021 and held it in 6 quarters.
  • Bessemer Group's Phathom Pharmaceuticals position peaked at $4K in Q1 2021.
  • 133 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2024.

Based on Bessemer Group's 13F filing for Q3 2024, filed 12 Nov 2024.